View highlights and coverage from leading international congresses
touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]
Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]
It was an absolute pleasure to speak with Dr David Pesqué (Universitat Autònoma de Barcelona, Barcelona, Spain) about his study investigating the skin reactions seen in response to mRNA COVID-19 vaccines. His presentation entitled ‘Clinical characterization of skin reactions due to mRNA COVID-19 vaccines at a tertiary-level hospital: a descriptive study’ was given at the […]
Dr David Rosmarin (Tufts Medical Center, Boston, MA, USA) kindly took the time to speak with touchIMMUNOLOGY about the results from the safety and efficacy studies investigating ruxolitinib cream in vitiligo. His presentation entitled ‘Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies’ was […]
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease. His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS […]
It was a pleasure to discuss with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) the current unmet needs in the treatment of patients with Crohn’s disease. Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli […]
It was a pleasure to meet with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) to explore the efficacy and safety findings from the phase 3 study of MV130 for the prevention of COPD exacerbations. The abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD […]
It was great to talk with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) around the abstract ‘Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations.’ (Presentation ID 207), which was presented at ERS International Congress 2021, 5-8 September 2021. Questions What is known about […]
Get the latest clinical insights from touchIMMUNOLOGY
